We are monitoring the impact of COVID-19 on APAC Cardiovascular Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date November, 2021
ID: 12417
Share on
Share on

Asia-Pacific Cardiovascular Drugs Market Research Report – Segmented By Drugs Type, Disease indication, End-Users and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: November, 2021
ID: 12417
Pages: 100

APAC Cardiovascular Drugs Market Size (2021 to 2026)

The size of the cardiovascular drugs market in the APAC region is estimated to be growing at a CAGR of 7.88% from 2021 to 2026 and worth USD 31.11 billion by 2026 from USD 21.29 billion in 2021.

An increase in the prevalence of cardiovascular diseases and other disorders such as high cholesterol, blood clod, and coronary artery disease are a few of the significant factors driving the market. In addition, the increase in cardiovascular diseases is due to the rise in the adoption of unhealthy lifestyle behaviours such as poor diet, physical inactivity, obesity, smoking, and alcoholism is increasing the risk of causing coronary artery disease, which is due to the development of fatty plaques in arteries that is atherosclerosis, which is further estimated to accelerate the demand for cardiovascular drugs in this region.

As cardiovascular disease is the leading cause of death globally, with Asia accounting for half of the cases, there is an increasing need for these treatments on the market. Other factors such as increasing awareness regarding cardiovascular health, supportive government policies, and rising new product launches by the key market players are expected to accelerate the market growth. Additionally, the increase in new technological advancements for developing innovative treatment procedures for treating cardiovascular diseases and medicines for reducing the risks associated with treatment treatments would drive demand for products in the market.

Furthermore, the rise in the initiatives and investment from government and non-government in research and development activities for developing new and effective drug therapies for cardiovascular illness is expected to provide lucrative growth opportunities to the market growth.

However, the stringent approval processes, as these processes are prolonged and time-consuming with strict government rules and regulations for the product entry, hampers the growth of the cardiovascular drugs market. Also, the increase in the availability of substitute products and treatments available in the market affects the demand for cardiovascular drugs. On the other hand, the high cost of the treatment and medication is predicted to be hindering the market growth.

This research report on the APAC cardiovascular drugs market has been segmented and sub-segmented into the following categories:

By Drug Type:

  • Antihypertensive
  • Antihyperlipidemic
  • Anticoagulants
  • Antiplatelet Drugs
  • Others

By Disease Indication:

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Arrhythmia
  • Others

By End-Users:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The Asia- Pacific is one of the fastest-growing regions globally in the cardiovascular drugs market, and it is anticipated to record a significant share in the global market during the forecast period. The regional market growth is attributed to the prevalence of rising chronic diseases, improving healthcare infrastructure, and favourable government policies. In addition, the emerging countries in the region, such as China, India, and Japan, are expanding the APAC regional market growth with a significant market share.

China accounts for the highest cardiovascular deaths among the other countries due to an increase in the adoption of a sedentary lifestyle, physical inactivity resulting in gaining overweight, as every year more than 4 million people die by suffering from cardiovascular disease. Therefore, with the rise in the new advancement in technology for developing innovative treatments and procedures for treating cardiovascular diseases, the market is expected to sign in the coming years.

On the other hand, India is expected to witness lucrative growth in the APAC cardiovascular drugs market during the forecast period. The increase in awareness among the people about the presence of treatment available in the market, the initiatives are taken by the government for developing advanced treatment procedures, and the rising investment in the medical and healthcare infrastructure are propelling the market growth.

KEY MARKET PLAYERS:

Companies playing a promising role in the APAC cardiovascular drugs market profiled in this report are Merck & Co, Sanofi S.A., Pfizer Inc., Bristol-Myers Squibb Company, and Novartis AG.

  1. Introduction                                   
    1. Market Definition            
    2. Scope of the report                     
    3. Study Assumptions                      
    4. Base Currency, Base Year and Forecast Periods             
  2. Research Methodology                             
    1. Analysis Design                
    2. Research Phases              
      1. Secondary Research     
      2. Primary Research          
      3. Data Modelling 
      4. Expert Validation          
    3. Study Timeline                 
  3. Report Overview                            
    1. Executive Summary                     
    2. Key Inferences                 
  4. Market Dynamics                           
    1. Impact Analysis                
      1. Drivers  
      2. Restraints          
      3. Opportunities   
    2. Regulatory Environment              
    3. Technology Timeline & Recent Trends                
  5. Competitor Benchmarking Analysis                                  
    1. Key Player Benchmarking            
      1. Market share analysis   
      2. Products/Service          
      3. Regional Presence        
    2. Mergers & Acquisition Landscape                       
    3. Joint Ventures & Collaborations              
  6. Market Segmentation                                
    1. Cardiovascular Drugs Market – By Drug Type:                
      1. Antihypertensive         
      2. Antihyperlipidemic       
      3. Anticoagulants  
      4. Antiplatelet Drugs        
      5. Others
      6. Market Size Estimations & Forecasts (2021-2026)      
      7. Y-o-Y Growth Rate Analysis      
      8. Market Attractiveness Index    
    2. Cardiovascular Drugs Market – By Disease Indication:               
      1. Hypertension 
      2. Hyperlipidaemia       
      3. Coronary Artery Disease           
      4. Arrhythmia       
      5. Others   
      6. Market Size Estimations & Forecasts (2021-2026)      
      7. Y-o-Y Growth Rate Analysis      
      8. Market Attractiveness Index    
    3. Cardiovascular Drugs Market – By End-Users:                
      1. Hospital Pharmacies     
      2. Retail Pharmacies        
      3. Online Pharmacies        
      4. Others
      5. Market Size Estimations & Forecasts (2021-2026)      
      6. Y-o-Y Growth Rate Analysis      
      7. Market Attractiveness Index    
  7. Geographical Landscape                            
    1. Asia Pacific                       
      1. By Country        
        1. China
        2. India
        3. Japan
        4. South Korea
        5. South East Asia
        6. Australia & NZ
        7. Rest of Asia-Pacific
      2. By Drug Type:   
      3. By Disease Indication:  
      4. By End-Users:    
  8. Key Player Analysis                        
    1. Merck & Co                      
      1. Business Description    
      2. Products/Service          
      3. Financials          
      4. SWOT Analysis  
      5. Recent Developments  
      6. Analyst Overview          
    2. Sanofi S.A.            
    3. Pfizer Inc.             
    4. Bristol-Myers Squibb Company               
    5. Novartis AG                      
  9. Market Outlook & Investment Opportunities                               
  10. 10.Appendix                           
      1. List of Tables              
      2. List of Figures             
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identifying the areas that are still untapped. 
  • The segment-level analysis in terms of drug type, disease indication, end-users, and region along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.
  1. Asia Pacific Cardiovascular Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  2. Asia Pacific Antihypertensive Market, By Region, From 2021 to 2026 (USD Billion)
  3. Asia Pacific Antihyperlipidemic Market, By Region, From 2021 to 2026 (USD Billion)
  4. Asia Pacific Anticoagulants Market, By Region, From 2021 to 2026 (USD Billion)
  5. Asia Pacific   Antiplatelet Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  6. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  7. Asia Pacific Cardiovascular Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  8. Asia Pacific Hypertension Market, By Region, From 2021 to 2026 (USD Billion)
  9. Asia Pacific Hyperlipidaemia Market, By Region, From 2021 to 2026 (USD Billion)
  10. Asia Pacific Coronary Artery Disease Market, By Region, From 2021 to 2026 (USD Billion)
  11. Asia Pacific   Arrhythmia Market, By Region, From 2021 to 2026 (USD Billion)
  12. Asia Pacific   Others Market, By Region, From 2021 to 2026 (USD Billion)
  13. Asia Pacific Cardiovascular Drugs Market, By End-Users, From 2021 to 2026 (USD Billion)
  14. Asia Pacific Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)
  15. Asia Pacific Retail Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)
  16. Asia Pacific    Online Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)
  17. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Billion)
  18. Japan Cardiovascular Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  19. Japan Cardiovascular Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  20. Japan Cardiovascular Drugs Market, By End-Users, From 2021 to 2026 (USD Billion)
  21. China Cardiovascular Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  22. China Cardiovascular Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  23. China Cardiovascular Drugs Market, By End-Users, From 2021 to 2026 (USD Billion)
  24. India Cardiovascular Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  25. India Cardiovascular Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  26. India Cardiovascular Drugs Market, By End-Users, From 2021 to 2026 (USD Billion)
  27. Australia Cardiovascular Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  28. Australia Cardiovascular Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  29. Australia Cardiovascular Drugs Market, By End-Users, From 2021 to 2026 (USD Billion)
  30. South Korea Cardiovascular Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  31. South Korea Cardiovascular Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  32. South Korea Cardiovascular Drugs Market, By End-Users, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample